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Boston, MassachusettsOBJECTIVES This study sought to determine whether the extent of late gadolinium enhancement
(LGE) can provide additive prognostic information in patients with a nonischemic dilated cardiomyopa-
thy (NIDC) with an indication for implantable cardioverter-deﬁbrillator (ICD) therapy for the primary pre-
vention of sudden cardiac death (SCD).
BACKGROUND Data suggest that the presence of LGE is a strong discriminator of events in patients
with NIDC. Limited data exist on the role of LGE quantiﬁcation.
METHODS The extent of LGE and clinical follow-up were assessed in 162 patients with NIDC prior to
ICD insertion for primary prevention of SCD. LGE extent was quantiﬁed using both the standard
deviation–based (2-SD) method and the full-width half-maximum (FWHM) method.
RESULTS We studied 162 patients with NIDC (65% male; mean age: 55 years; left ventricular ejection
fraction [LVEF]: 26  8%) and followed up for major adverse cardiac events (MACE), including cardiovas-
cular death and appropriate ICD therapy, for a mean of 29  18 months. Annual MACE rates were sub-
stantially higher in patients with LGE (24%) than in those without LGE (2%). By univariate association, the
presence and the extent of LGE demonstrated the strongest associations with MACE (LGE presence, haz-
ard ratio [HR]: 14.5 [95% conﬁdence interval (CI): 6.1 to 32.6; p < 0.001]; LGE extent, HR: 1.15 per 1%
increase in volume of LGE [95% CI: 1.12 to 1.18; p < 0.0001]). Multivariate analyses showed that LGE
extent was the strongest predictor in the best overall model for MACE, and a 7-fold hazard was observed
per 10% LGE extent after adjustments for patient age, sex, and LVEF (adjusted HR: 7.61; p < 0.0001). LGE
quantitation by 2-SD and FWHM both demonstrated robust prognostic association, with the highest
MACE rate observed in patients with LGE involving >6.1% of LV myocardium.
CONCLUSIONS LGE extent may provide further risk stratiﬁcation in patients with NIDC with a cur-
rent indication for ICD implantation for the primary prevention of SCD. Strategic guidance on ICD therapy
by cardiac magnetic resonance in patients with NIDC warrants further study. (J Am Coll Cardiol Img
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945onischemic dilated cardiomyopathy
(NIDC) is characterized by ventricularA B B R E V I A T I O N S
A N D A C R O N YM S
CMR = cardiac magnetic
resonance
EF = ejection fraction
FWHM = full-width
half-maximum
ICD = implantable cardioverter-
deﬁbrillator
LGE = late gadolinium
enhancement
MACE = major adverse
cardiac events
NIDC = nonischemic dilated
cardiomyopathy
SCD = sudden cardiac death
VT = ventricular tachycardiadilation and impairment of cardiac func-
tion in the absence of signiﬁcant coronary
artery disease (1). The annual mortality rate is re-
ported at approximately 7%, with one-third of
deaths classiﬁed as sudden and likely arrhythmia
mediated (2). Implantable cardioverter-deﬁbrillators
(ICDs) reduce mortality in patients with NIDC
and an ejection fraction (EF) of #35% (3). How-
ever, the majority of patients with NIDC do not
beneﬁt from ICD implantation (4,5), and signiﬁ-
cant procedural risks and expensive downstream
healthcare costs exist (6). Therefore, research to
develop methods of improved risk stratiﬁcation
beyond conventional measures of cardiac function
and functional status would appear to be of signif-
icant value (7).
Myocardial ﬁbrosis identiﬁed using late gadolin-
ium enhancement (LGE) cardiac magnetic reso-
nance (CMR) has been shown to be a predictor of
death, ICD therapy, and heart failure hospitalizations
in patients with a NIDC (8–11). Outcomes data in
patients with NIDC are further supported by mech-
anistic studies demonstrating that the presence of
myocardial scar by LGE-CMR is associated with
ventricular arrhythmias (12,13). The presence of
LGE provides prognostic information; however,
there are limited data onwhether quantiﬁcation of the
extent of LGE provides prognostic information
beyond identiﬁcation of the presence of scar.
Furthermore, these patients are at risk for the pro-
gression of heart failure and arrhythmic events, and an
assessment of the differentiating ability of LGE for an
arrhythmic versus a heart failure endpoint may be of
value. Therefore, we aimed speciﬁcally to address
whether quantiﬁcation of LGE provides prognostic
information about the risk for heart failure and the
risk for arrhythmia in patients with NIDC under-
going ICD implantation for the primary prevention
of sudden cardiac death (SCD). We hypothesized
that a greater extent of scar would be associated with
an increased risk for adverse outcomes.
METHODS
Study population. We performed a prospective
observational study in which we collected data onAssociation Fellow to Faculty Grant (12FTF12060588, to Dr. Neilan),
HL094301-02, to Dr. Neilan), and National Institutes of Health researc
Dr. Kwong). All authors have reported that they have no relationships releva
Manuscript received March 5, 2012; revised manuscript received April 18, 2consecutive patients with NIDC who underwent a
CMR study with gadolinium followed by an ICD
insertion. CMR studies were performed between
2003 and 2011 at Brigham and Women’s Hospital
(BWH) and at Massachusetts General Hospital
(MGH) in Boston, Massachusetts. Patients were
entered into a registry at the time of the CMR
study. We then identiﬁed all those who had an ICD
inserted for the primary prevention of SCD. The
diagnosis of NIDC was based on World Health
Organization deﬁnitions (14). Signiﬁcant coronary
disease was excluded by both clinical history and
cardiac investigation. Speciﬁcally, the majority of
patients in the cohort (156 of 162) underwent
coronary angiography to exclude signiﬁcant coro-
nary artery disease (>50% luminal narrowing). The
remaining 6 patients, ages 18, 20, 22, 22, 24, and 30
years, had undergone recent negative imaging stress
testing, and none of the patients had LGE
in the distribution typical of myocardial
infarction. Other exclusion criteria
included an inﬁltrative cardiomyopathy
based either on history or CMR ﬁndings
and a prior indication for placement of an
ICD (such as syncope, cardiac arrest, or
sustained ventricular arrhythmias). The
protocol was approved by the Human
Subjects Review Committee at both
hospitals.
CMR protocol. All images were acquired
with electrocardiography gating and
breath-holding and with the patient in the
supine position. Subjects were imaged on
either a 1.5-T (n ¼ 75) or a 3.0-T (n ¼ 87)
CMR system (Signa CV/I HDXt plat-
form, General Electric Healthcare, Wau-
kesha, Wisconsin, and Tim Trio, Siemens,
Erlangen, Germany, respectively). Both CMR
protocols consisted of cine steady-state free preces-
sion imaging for cardiac function (BWH: typical
repetition time: 3.4 ms; echo time: 1.2 ms; in-plane
spatial resolution: 1.6  2 mm; MGH: typical
repetition time: 3.5 ms; echo time: 1.4 ms; in-plane
resolution: 2.0  2.0 mm) and LGE imaging
for myocardial ﬁbrosis (BWH: repetition time:
4.8ms; echo time: 1.3ms; inversion time: 200–300ms;
MGH: repetition time: 7.1 ms; echo time: 3.1 ms;a National Institutes of Health T32 Training Grant (T32
h grants (R01HL090634-01A1, MJH; R01HL091157, to
nt to the contents of this paper to disclose.
013, accepted May 5, 2013.
Neilan et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 9 , 2 0 1 3
LGE, SCD, and NIDC S E P T E M B E R 2 0 1 3 : 9 4 4 – 5 4
946inversion time: 150 to 300 ms). A segmented
inversion-recovery pulse sequence for LGE was used
starting 10 to 15 min after a cumulative dose of 0.15
mmol/kg of gadolinium diethylenetriaminepenta-
acetic acid. Cine imaging and LGE imaging were
obtained in 8 to 14 matching short-axis (BWH: 8
mm thick with 0-mm spacing; MGH: 8 mm thick
with 2-mm spacing) and 3 radial long-axis planes. To
determine whether active myocarditis was playing a
role in the reduced EF, a T2-weighted inversion re-
covery prepared fast-spin echo sequence was per-
formed using 3 short-axis slices of 12-mm thickness
at the base, mid, and apex and a single long-axis slice
in a 4-chamber view (15). Qualitatively, the sequence
was considered abnormal if there were patchy areas
of high T2 signal intensity indicating focal or
regional edema. All images were analyzed with
specialized software (Mass Research, University
Medical Centre, Leiden, the Netherlands) by re-
searchers blinded to clinical outcome.
Late gadolinium enhancement. LGE was inter-
preted as present or absent by the consensus of
2 CMR-trained physicians. LGE was considered
present only if conﬁrmed on both short-axis and
matching long-axis myocardial locations. LGE was
quantiﬁed by a semiautomatic detection method
using two previously validated methods (16,17).
Both methods measured the mass of LGE (in
grams), which was then expressed as a percentage of
total left ventricular (LV) mass. LGE was quantiﬁed
using a signal intensity threshold of >2 SD above a
remote reference region and also using regions
deﬁned as above 50% of maximal signal intensity of
the enhanced area (full-width at half maximum
[FWHM]). The distribution of LGE was charac-
terized as either midwall, epicardial, focal/involving
the right ventricular insertion points, or diffuse. If
more than one pattern was present, the distribution
was characterized on the basis of the predominant
pattern.
Echocardiography. LV mass was derived from the
2-dimensional measurements of intraventricular
septal thickness, posterior wall thickness, and LV
internal dimensions in diastole, as recommended
by the American Society of Echocardiography
(18,19). LVEF was measured using the biplane
method of discs. Pulmonary artery systolic pressure
was estimated from the tricuspid regurgitant velocity
plus an estimate of right atrial pressure derived from
the inferior vena cava.
Methods of clinical follow-up. We ascertained mor-
tality using the Social Security Death Index and
conﬁrmed using electronic chart review. Adjudication
of ICD events were performed by 2 cardiacelectrophysiologists (S.B.D., M.T.) blinded to all
other clinical data; events were classiﬁed as appro-
priate if they were a result of ventricular tachyar-
rhythmia according to established criteria (20).
Patients were followed up at 3- to 6-month intervals
via clinic visits or, if appropriate, transmitted ICD
data. Survival analyses were performed for 3 clinical
endpoints: 1) the primary endpoint of major adverse
cardiac events (MACE), which included a composite
of cardiovascular death and a ventricular arrhythmia,
terminated by the ICD (either antitachycardia pacing
or ICD shock); 2) a secondary endpoint of
arrhythmia, deﬁned as a combination of appropriate
antitachycardia pacing (ATP) therapy, appropriate
ICD shock, and SCD; and 3) a third endpoint, heart
failure, deﬁned as heart failure–related death or heart
failure hospitalization. The duration of follow-up was
determined from the CMR study date to the
occurrence of an endpoint. If no endpoint occurred,
the patient’s data were censored at the date of last
clinical follow-up. Complete follow-up was available
for all patients.
Statistical analysis. Continuous data are presented
as mean  SD. Continuous data were compared
using an unpaired Student t test or Mann-Whitney
nonparametric test as appropriate. Nominal data are
presented as number and percentages and were
compared using a chi-square test. We randomly
selected 15 patients with LGE and compared the
measurement of LGE volume using both the 2-SD
method and the FWHM method. Cohen’s kappa
was applied to measure inter-reader and intrareader
agreement on the volume of LGE using the
following grading: 0 to 0.2 (poor), 0.21 to 0.4 (fair),
0.41 to 0.6 (moderate), 0.61 to 0.8 (substantial),
and 0.81 to 1.0 (nearly perfect) (21). To test for
correlation between the different methods of
measuring LGE volume, a Spearman rank corre-
lation coefﬁcient was used. The hazard ratio (HR)
for the prediction of events was calculated for each
of the outcomes using a Cox regression model. For
each outcome of interest, we considered all of the
signiﬁcant variables in the univariate analysis and
sought the best overall multivariate models for the
composite endpoint, by stepwise-forward selection,
with a probability to enter set at p < 0.05 and to
remove the effect from the regression at p < 0.05.
We also performed a second multivariate analysis
of the associations with established risk factors for
adverse outcomes in patients with a cardiomyop-
athy (age, sex, LVEF, LV end-diastolic volume,
and diabetes) and included LGE in this clinical
model. Event curves were determined according to
the Kaplan-Meier method, and comparisons of
Table 1. Baseline Patient Characteristics According to the Presence or Absence of
Late Gadolinium Enhancement
All Patients
(n [ 162)
LGE Negative
(n [ 81)
LGE Positive
(n [ 81) p Value
Age, yrs 55  14 55  11 55  15 0.56
Male 106 (65) 47 (58) 59 (73) 0.07
Cardiovascular risk factors
Diabetes 41 (25) 21 (26) 20 (25) 1.00
Hypertension 63 (39) 32 (40) 31 (38) 1.00
Atrial ﬁbrillation 40 (25) 18 (22) 22 (27) 0.59
Family history of DCM 13 (8) 6 (7) 7 (9) 1.00
Alcohol excess 6 (4) 3 (4) 3 (4) 1.00
NYHA functional class
II 91 (56) 46 (57) 45 (56) 1.00
III 71 (44) 35 (43) 36 (44) 1.00
Heart failure duration,
months
13 (9,16) 13 (8–18) 13 (10–16) 0.77
CMR to ICD, months 0.5 (0.25–2.5) 1 (0.5–3) 1 (0.5–2) 0.67
CRT 38 (24) 18 (22) 20 (25) 0.56
BMI, kg/m2 29  6 29  4 29  7 0.75
SBP, mm Hg 115  18 115  17 115  8 0.48
DBP, mm Hg 71  11 72  10 70  11 0.39
Heart rate, beats/min 74  13 76  13 72  14 0.66
Medication
ACE/ARB 154 (95) 76 (94) 78 (96) 1.00
Beta-blocker 158 (98) 79 (98) 79 (98) 1.00
Spironolactone 67 (41) 30 (37) 32 (40) 0.87
Diuretics 98 (61) 50 (62) 40 (49) 0.16
Antiarrhythmic 24 (15) 11 (14) 13 (16) 0.83
Coumadin 59 (36) 27 (33) 32 (40) 0.51
Aspirin 59 (36) 28 (35) 31 (38) 0.74
Statin 58 (36) 28 (35) 30 (37) 0.87
QRS duration, ms 117  30 114  33 120  31 0.19
QTc duration, ms 459  30 457  39 461  38 0.69
GFR, ml/min/1.73 m2 70  20 73  19 67  21 0.11
Values are mean  SD, n (%), or median (IQR).
ACE/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI ¼ body mass
index; CMR to ICD ¼ time from performance of the cardiac magnetic resonance scan to insertion of
implantable cardioverter-deﬁbrillator; CRT ¼ cardiac resynchronization therapy; DCM ¼ dilated congestive
cardiomyopathy; DBP ¼ diastolic blood pressure; GFR ¼ glomerular ﬁltration rate using the Modiﬁcation of
Diet in Renal Disease formula done at the time of the CMR; Heart failure duration ¼ time from onset of
symptoms to CMR; IQR ¼ interquartile range; LGE Negative ¼ patients without late gadolinium
enhancement; LGE Positive ¼ patients with late gadolinium enhancement; NYHA ¼ New York Heart
Association; SBP ¼ systolic blood pressure.
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the log-rank test. Receiver-operator characteristic
(ROC) curves were constructed to determine
optimal cutoff (value with the maximal sensitivity
and speciﬁcity) of LGE extent as measured using
both the 2-SD method and the FWHM method
to predict MACE. Based on the available litera-
ture (8), expecting a 15% difference in the MACE
rates between patients with and without LGE,
we calculated that we would need 76 subjects in
each group (with and without LGE) in order to
ﬁnd a statistically signiﬁcant difference with a
2-tailed p value <0.05. SAS (SAS Institute Inc.,
Cary, North Carolina) was used for statistical
analysis.
RESULTS
In total, a cohort of 254 patients were identiﬁed.
From this cohort, 96 patients were excluded due to a
prior indication for ICD insertion (n ¼ 45), LGE in
a typical infarct pattern (n ¼ 29), or inﬁltrative
cardiomyopathy (n ¼ 22). Of the 29 patients
excluded due to LGE in an infarct pattern, 23 un-
derwent negative stress testing prior to the CMR
study, and 6 underwent coronary angiography. In
the former group of 23 patients, based on the results
of the CMR study, coronary angiography was sub-
sequently performed, with, signiﬁcant coronary
disease (>50% luminal narrowing) found in 22
patients. Among the 6 patients with prior angiog-
raphy, all had coronary disease, but of a severity less
than the 50% luminal narrowing. Of the 22 patients
with an inﬁltrative cardiomyopathy diagnosed based
on the CMR ﬁndings, 12 had hemochromatosis, 6
had cardiac sarcoidosis, and 4 had cardiac amyloid.
The ﬁnal cohort consisted of 162 patients who
underwent ICD placement, and all were included in
the analysis (Tables 1 and 2). There were 106 men
and 56 women referred for a CMR study, with a
mean LVEF by echocardiography of 26  8%.
Median follow-up was 26 months (interquartile
range [IQR]: 15 to 43 months; mean: 29  18
months). The CMR study was performed at a
median of 13 months (IQR: 9 to 16 months) after
onset of heart failure. The majority of patients
(56%) were New York Heart Association (NYHA)
functional class II; the remainder were functional
class III. Among the entire cohort, 98% were pre-
scribed a beta-blocker, 95% either an angiotensin-
converting enzyme inhibitor or an angiotensin II
receptor blocker, and 41% an aldosterone antago-
nist. Thirty-eight patients (24%) underwent cardiac
resynchronization therapy at the time of ICDinsertion. None of the patients in the entire cohort
had qualitative evidence of myocardial edema by T2
imaging.
Late gadolinium enhancement. LGE was present in
81 patients (50%) (Tables 1 and 2). The LGE
pattern was mid-myocardial in 42 patients (52%),
epicardial in 21 (26%), focal/insertion points in 16
(20%), and diffuse in 2 (2%). Patients were grouped
Table 2. Imaging Characteristics of the Entire Cohort and Stratiﬁed According
to the Presence or Absence of LGE
All Patients
(n [ 162)
LGE Negative
(n [ 81)
LGE Positive
(n [ 81) p Value
Echocardiography
LVEF, % 26  8 27  9 24  8 0.40
LVIDd, mm 61  10 60  8 62  12 0.58
Estimated PASP, mm Hg 37  12 34  12 39  13 0.13
CMR
Field strength, 3.0-T vs. 1.5-T, % 87  54 44  54 43  53 0.99
LVEDV, ml 270  93 267  91 274  97 0.63
LVEDV index, ml/m2 140  50 136  43 143  51 0.45
LVESV, ml 199  89 191  85 207  94 0.35
LVESV index, ml/m2 103  47 98  41 109  50 0.31
LVEF, % 28  9 30  7 26  9 0.17
LV mass, g 158  47 156  48 160  52 0.86
LV mass index, g/m2 81  24 80  24 82  25 0.65
RVEDV, ml 164  62 160  61 168  65 0.81
RVEDV index, ml/m2 84  31 81  29 87  32 0.34
RVESV, ml 100  55 97  55 103  59 0.31
RVESV index, ml/m2 51  28 49  26 53  30 0.34
RVEF, % 41  13 44  12 37  13 0.12
LGE
2-SD, % of LV mass 9  5
FWHM, % of LV mass 6  4
Epicardial 21  26
Mid-myocardial 42  52
Focal/insertion points* 16  20
Diffuse 2  2
Values are mean  SD. *Predominant location of LGE in anterior or posterior right ventricular insertion
points.
CMR ¼ cardiac magnetic resonance; FWHM ¼ full-width half-maximum method; LGE ¼ late gadolinium
enhancement; LVEDV ¼ left ventricular end diastolic volume; LVEF ¼ left ventricular ejection fraction;
LVESV ¼ left ventricular end systolic volume; LVIDd ¼ left ventricular internal dimension in diastole;
PASP ¼ pulmonary artery systolic pressure; RVEDV ¼ right ventricular end diastolic volume; RVEF ¼ right
ventricular ejection fraction; RVESV ¼ right ventricular end systolic volume.
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(Tables 1 and 2). Although glomerular ﬁltration
rate, LVEF, and right ventricular EF were lower
and estimated pulmonary artery systolic pressure
was higher among patients with LGE, these dif-
ferences were not statistically signiﬁcant (e.g.,
LVEF: 26  9% vs. 30  7% in LGE positive vs.
LGE negative, respectively; p ¼ 0.17). The volume
of LGE as a percentage of the total LV volume was,
on average, 50% greater using the 2-SD method in
comparison to the FWHM method (9  5% by the
2-SD method vs. 6  4% using the FWHM
method; p < 0.001) (Table 2). However, there was a
close correlation between the measurement of
LGE volume using both methods (r ¼ 0.91; p <0.001). The kappa coefﬁcients of agreement for the
measurement of LGE extent using the 2-SD
method were 0.67 (inter-reader) (mean difference
in extent of LGE: 0.8%) and 0.65 (intrareader)
(mean difference in extent of LGE: 1.1%). The
corresponding values using the FWHM method
were 0.68 (mean difference in extent of LGE:
0.5%) and 0.70 (mean difference in extent of
LGE: 0.5%).
Major adverse cardiac events. There were 51 events
among the 162 patients during a mean of 29  18
months of follow-up (median follow-up: 26
months; IQR: 15 to 43 months). Forty-seven of
these events were in patients with LGE (event
rate: 24%/year), and 4 were in patients without
LGE (event rate: 2%/year). Among LGE-positive
patients, there were 19 episodes of ATP, 15
appropriate ICD discharges, and 13 cardiovascular
deaths. An example of a patient with LGE who
underwent ICD placement followed by an appro-
priate ICD discharge is shown in Figure 1. The 4
adverse events in LGE-negative patients consisted
of 2 ATP events, 1 appropriate ICD discharge,
and 1 cardiovascular death. The initial event, an
ATP event, occurred 13 months after ICD im-
plantation. The appropriate ICD discharge
occurred 33 months after insertion, and the car-
diovascular death occurred at 64 months after ICD
insertion from intractable heart failure. The LGE-
negative patients who had events were male, with a
mean age of 51  20 years, a mean LV end-
diastolic volume of 295  112 ml, a mean
LVEF of 22  9%, a mean right ventricular EF of
37  18%, and a mean QRS width of 114  46
ms. The presence of LGE had a sensitivity of 92%
(95% conﬁdence interval [CI]: 0.80 to 0.98), a
speciﬁcity of 69% (95% CI: 0.60 to 0.78), a pos-
itive predictive value of 58%, and a negative pre-
dictive value of 95% for the occurrence of MACE.
The Cox regression analysis revealed that the
presence of LGE (HR: 14.5; 95% CI: 6.06 to
32.61; chi-square: 18.75; p < 0.001) and the
extent of LGE (by 2-SD: HR: 1.15 for each 1%
absolute increase in LGE by volume [95% CI:
1.12 to 1.18; chi-square: 43.26; p < 0.0001]; by
FWHM: HR: 1.16 for each 1% increase in LGE
extent by volume [95% CI: 1.12 to 1.20; chi-
square: 41.6; p < 0.0001]) demonstrated the
strongest unadjusted association with MACE
(Table 3). We did not ﬁnd an association between
CMR ﬁeld strength and MACE (HR: 1.03; 95%
CI: 0.59 to 1.82; chi-square: 0.01; p ¼ 0.91)
(Table 3). In a multivariate model, LGE extent
was the strongest covariate selected to form the
Figure 1. LGE and Adverse Events
Short-axis views of the ventricle after a segmented inversion–recovery pulse sequence for late gadolinium enhancement (LGE) starting 10 to
15 min after the administration of a cumulative dose of 0.15 mmol/kg of gadolinium diethylenetriaminepentaacetic acid in a patient without
LGE (A) and with mid-myocardial LGE (B). The extent of LGE was 18% using the 2-SD method. Telemetry from a dual-chamber implantable
cardioverter-deﬁbrillator (ICD) transmission from the patient in (B), showing initially sinus rhythm, then some ventricular ectopics, followed by
a regular ventricular rhythm with a cycle length of 220 to 230 ms, which triggered a 34-joule deﬁbrillator discharge.
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(Table 4). In a clinical model, in which we tested
the association between LGE, age, sex, LVEF, LV
end-diastolic volume, and diabetes and MACE,
we found that the presence and the extent of LGE
were the strongest predictors of adverse events
(Table 5).
When the endpoint of arrhythmia was consid-
ered, both the presence of LGE (HR: 14; 95% CI:
4.39 to 45.65; chi-square: 19.2; p < 0.0001) and the
extent of LGE (by 2-SD: HR: 1.17 per each 1%
absolute increase in volume of LGE; 95% CI: 1.12
to 1.22; chi-square: 52.1; p < 0.0001) were strongly
associated with a combined arrhythmic outcome of
ATP, ICD discharge, and non–heart failure car-
diovascular death. The location of LGE was not
associated with the occurrence of an arrhythmic
endpoint. There were no other signiﬁcant univariate
associations with an arrhythmic endpoint. When
a heart failure endpoint was considered, NYHA
functional class II (HR: 12.2; 95% CI: 1.09 to 4.42;
chi-square 4.9; p ¼ 0.03), systolic blood pressure
(HR: 0.97; 95% CI: 0.95 to 0.99; chi-square: 5.9;p ¼ 0.01), glomerular ﬁltration rate (HR: 0.98; 95%
CI: 0.97 to 0.99; chi-square: 4.2; p ¼ 0.03), esti-
mated pulmonary artery systolic pressure (HR: 1.03;
95% CI: 1.00 to 1.06; chi-square: 4.3; p ¼ 0.03),
right ventricular EF (HR: 0.97; 95% CI: 0.94
to 0.99; chi-square: 5.8; p ¼ 0.01), LGE extent
(by FWHM: HR: 1.15; 95% CI: 1.08 to 1.23;
chi-square: 20.2; p < 0.0001), and LGE location
involving the epicardium (HR: 4.88; 95% CI: 1.94
to 12.2; chi-square: 11.4; p ¼ 0.0007) demon-
strated signiﬁcant univariate association with the
combined endpoint of heart failure hospitalization
and heart failure death. The presence of LGE was
not associated with this combined heart failure
endpoint.
Extent of LGE and outcome. ROC curves among
patients with LGE were generated to determine
whether the extent of LGE could help to identify a
group at further increased risk for MACE. Analysis
of ROC curves revealed a percentage of LGE by
volume of >6.1% using the 2-SD method (area
under the curve: 0.92; sensitivity: 90%; speciﬁcity:
95%) and >4.4% using the FWHM method (area
Table 3. Univariate Analysis for Association With MACE
HR 95% CI
LR
Chi-Square p Value
Age 1.01 0.99–1.03 1.25 0.26
Male 2.03 1.01–4.06 4.01 0.04
Year of study enrollment 1.14 0.96–1.36 2.29 0.13
CRT 0.83 0.43–1.64 0.26 0.61
Diabetes 1.19 0.64–2.22 0.31 0.57
Hypertension 1.23 0.71–2.17 0.56 0.45
NYHA functional class II 0.75 0.44–1.31 0.99 0.32
NYHA functional class III 1.32 0.76–2.30 0.99 0.32
SBP 1.00 0.99–1.02 0.13 0.72
DBP 1.01 0.98–1.04 0.51 0.47
Heart rate 1.01 0.99–1.04 0.51 0.29
Antiarrhythmic drugs 1.55 0.79–3.06 1.65 0.19
QRS duration 1.00 0.99–1.01 0.14 0.70
GFR 0.98 0.97–0.99 5.71 0.02
Echocardiography
Estimated PASP 0.99 0.96–1.03 0.12 0.73
Cardiac magnetic
resonance
Field strength 3.0-T
(vs. 1.5-T)
1.03 0.59–1.82 0.01 0.91
LVEDV 1.00 0.99–1.01 0.97 0.32
LVESV 1.00 0.99–1.00 0.47 0.49
CMR-derived LVEF 1.00 0.97–1.03 0.07 0.78
CMR-derived
LV mass index
1.00 0.99–1.01 0.48 0.48
RVEDV 1.00 0.99–1.01 2.19 0.13
RVESV 1.00 0.99–1.01 2.24 0.13
RVEF 0.99 0.97–1.02 0.75 0.38
LGE 14.50 6.06–32.61 18.75 <0.001
Extent (2-SD)* 1.15 1.12–1.18 43.26 <0.0001
Extent (FWHM)* 1.16 1.12–1.20 41.57 <0.0001
Epicardial 1.63 0.88–3.04 2.39 0.12
Mid-myocardial 0.92 0.52–1.63 0.08 0.77
Focal/insertion points 0.90 0.79–1.01 3.36 0.08
Diffuse 3.12 0.73–13.29 2.37 0.12
*LGE extent HR is for each 1% absolute increase in LGE volume.
HR ¼ hazard ratio; CI ¼ conﬁdence interval; LR ¼ likelihood ratio; MACE ¼ major adverse cardiac events;
other abbreviations as in Tables 1 and 2.
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950under the curve: 0.93; sensitivity: 86%; speciﬁcity:
96%) as the optimal combination of sensitivity and
speciﬁcity for the prediction of events (Fig. 2).
Kaplan-Meier curves were generated for event-free
survival among patients by both the presence or
absence of LGE and the extent of LGE using the
two methods of measurement (Fig. 3). Patients with
an LGE extent of >6.1% represented a high-risksubgroup in which there were 46 events, or a cu-
mulative event rate of over 50%/year.
D I SCUSS ION
We tested whether the extent of LGE among pa-
tients with a NIDC who underwent ICD implan-
tation for the primary prevention of SCD could
provide additive prognostic information. The extent
of LGE provided the strongest independent asso-
ciation, with both a composite endpoint of cardio-
vascular death and a ventricular arrhythmia or the
arrhythmic endpoint. The extent of LGE provided
supplementary information beyond conventional
risk stratiﬁcation, identifying one group at an
increased risk and one at a decreased risk for adverse
events.
These ﬁndings are complementary to, and build
on, those from previously published reports on the
prognostic value of LGE in patients with an NIDC
(9–11,22). Wu et al. (10) followed up a similar
population of 65 patients with NIDC referred for
ICD implantation for a median of 1.4 years. In that
study, LGE was identiﬁed in 42% of patients with a
mean LVEF of 24%, and was associated with an 8-
fold higher risk for a composite of CV death, hos-
pitalization for heart failure, and ICD therapy.
However, heart failure hospitalizations accounted
for the majority of outcomes. Iles at al. (11) per-
formed CMR imaging in 61 patients with NIDC
who underwent ICD insertion, and followed them
up for a median of 1.6 years. Scar by CMR was
identiﬁed in 51% and was associated with ICD
therapy alone and a composite of death, the need for
ICD therapy, and the need for heart trans-
plantation. Indeed, in that study, not a single pa-
tient without LGE had an adverse cardiac event.
We extend these data, and provide additive infor-
mation regarding measuring the extent of LGE.
Quantiﬁcation of the extent of LGE using either of
two validated clinical methods demonstrated that
the extent of LGE provided the strongest associa-
tion with adverse events.
One of the primary aims of this study was to
determine whether scar imaging by LGE could
further assist in the stratiﬁcation of patients in
whom an ICD is currently indicated (23). Identi-
ﬁcation of low-risk patients is clinically relevant, as
it is recognized that a substantial proportion of
patients who are currently referred for ICD im-
plantation based on EF do not derive beneﬁt (2).
EF is the most widely used measure of LV function,
and lower EF is accepted in general to be the
strongest predictor of mortality in patients with
Table 5. Multivariate Clinical Model for Association
With MACE
HR 95% CI
LR
Chi-Square p Value
Age 1.00 0.99–1.03 0.38 0.54
Sex 1.37 0.63–2.94 0.63 0.43
LVEDV 1.00 0.99–1.01 2.67 0.10
LVEF 1.04 0.99–1.08 3.52 0.06
Diabetes 1.11 0.58–2.10 0.09 0.77
LGE 18.9 5.82–61.3 23.9 <0.0001
Extent (2-SD) 5.94 3.92–9.00 32.5 <0.0001
Abbreviations as in Tables 1 to 3.
Table 4. Multivariate Analysis for Association With MACE
HR 95% CI
LR
Chi-Square p Value
CMR
HR 1.04 1.02–1.06 7.8 0.005
LGE 6.21 1.73–22.2 12.5 0.0004
Extent (2-SD)* 1.16 1.07–1.21 39.3 <0.0001
*LGE extent HR is for each 1% absolute increase in LGE volume.
Abbreviations as in Tables 1 to 3.
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951NIDC (1). However, measurement variability is 5%
to 8% (7), and LVEF is recognized to have poor
positive predictive value in patients referred for an
ICD (7). One of the limitations of studies such as
ours is the appropriate deﬁnition of events. It is clearS
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Figure 2. ROC Curves for LGE Extent Using 2 Methods for the Asso
Analysis revealed that the percentage of LGE by volume of >6.1% usin
speciﬁcity: 95%) (A) and >4.4% using the full-width half-maximum (FW
96%) (B) for prediction of events. ROC ¼ receiver-operating characterisfrom studies such as DEFINITE (Deﬁbrillator in
Non-Ischemic Cardiomyopathy Treatment Evalu-
ation) (2) that the ICD therapy rate is far higher
than the SCD rate in the control group, suggesting
that metrics such as ICD discharge and ATP may
overestimate the beneﬁt of ICD insertion (2).
Allowing for this likely overestimation, we found
that one death occurred among the patients without
LGE; that the initial ICD therapy occurred after 1
year of follow-up; and that, cumulatively, there were
only 4 total events in the LGE-negative cohort.
These data suggest that even in a cohort considered
at high risk based on EF, the absence of LGE can
be useful in additive risk stratiﬁcation. These data
should support further research into the role of
estimation of myocardial scar and risk stratiﬁcation
in patients with NIDC. Also, further work on
whether novel CMR-based measures of myocardial
ﬁbrosis, such as T1 measurements, could provide
further risk stratiﬁcation seems warranted. Indeed,
measurement of myocardial T1 pre- and post-
contrast values may provide a more sensitive mea-
sure for expansion of the myocardial extracellular
matrix (24,25).
Conversely, the extent of LGE also identiﬁed a
group at substantially elevated risk for events. When
we conﬁned our analysis to LGE-positive patients
with an LGE of >6.1% using the 2-SD method, we
found an overall event rate of 50%/year. Quantiﬁ-
cation of the extent of LGE may identify a group
who may beneﬁt from more advanced electrophys-
iological therapy, such as VT ablation, orS
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g the 2-SD method (area under the curve: 0.92; sensitivity: 90%;
HM) method (area under the curve: 0.93; sensitivity: 86%; speciﬁcity:
tic; other abbreviations as in Figure 1.
P < 0.001
LGE Positive
LGE Negative
No. at Risk
 81 66 37 21 3
 81 50 24 13 4
E
v
e
n
t
-
f
r
e
e
 
S
u
r
v
i
v
a
l
 
(
%
)
Months of Follow-up
A
LGE vs. No LGE
0 15 30 45 60
0
20
40
60
80
100
P < 0.001 LGE > 6.1%
LGE < 6.1%
No. at Risk
 109 88 51 27 6
 53 29 11 8 5
E
v
e
n
t
-
f
r
e
e
 
S
u
r
v
i
v
a
l
 
(
%
)
Months of Follow-up
B
LGE Vol. > or < 6.1% (2-SD)
0 15 30 45 60
0
20
40
60
80
100
LGE+
LGE –
LGE <6.1%
LGE >6.1%
LGE > 4.4%
LGE < 4.4%
No. at Risk
 113 92 55 31 10
 49 25 7 4 1
E
v
e
n
t
-
f
r
e
e
 
S
u
r
v
i
v
a
l
 
(
%
)
Months of Follow-up
C LGE Vol. > or < 4.4% (FWHM)
0 15 30 45 60
0
20
40
60
80
100
LGE <4.4%
LGE >4.4%
Figure 3. Event-Free Survival
Kaplan-Meier curves displaying event-free survival in cohorts according to: (A) the dichotomous presence or absence of LGE; (B) an extent of
LGE of >6.1% or <6.1% of the volume of the left ventricle, as measured using the 2-SD method; and (C) an extent of LGE of >4.4% or <4.4%
of the volume of the left ventricle, as measured using the FWHM method. Abbreviations as in Figures 1 and 2.
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952involvement of specialist heart failure services.
However, the optimum method for measurement of
LGE is debated. Although current guidelines
recommend using the 2-SD method (26), data
suggest that the use of this technique leads to an
overestimate of the extent of LGE in comparison to
other techniques (27). Additive to this, we found
that the extent of LGE using the 2-SD method was
50% greater than that found using the FWHM
method. However, there was a strong association
between the 2 measures; both methods provided
similar additive information in patients with a
reduced EF, and the main difference was in the
deﬁnition of an optimal cutoff value for the pre-
diction of adverse events.
Study limitations. This study should be interpreted
within the context of the design format. We spe-
ciﬁcally studied patients referred for workup of a
cardiomyopathy. Referral for a CMR study among
this cohort is not standard routine within our in-
stitutions. We cannot exclude that clinical features
other than the presence of a reduced EF could haveinﬂuenced referral for a CMR. However, none of
the patients in this study had a prior indication for
an ICD, none had an alternative diagnosis other
than NIDC, and all had manifested heart failure for
a median duration of over a year. Heart failure
events that were not captured within the Partners
System of hospitals were not independently veriﬁed
and were documented on the basis of a patient
questionnaire and conﬁrmation from the primary
providers. We recorded the medical therapy at the
time of the CMR study. Patients were enrolled over
a long period, and 2 limitations should be noted as a
result: both the overall therapy for heart failure
evolved and improved over this period and patient-
speciﬁc therapies such as aldosterone system
blockers and diuretics varied over this long period.
LGE-determined myocardial ﬁbrosis measures focal
or replacement ﬁbrosis and likely underestimates the
presence and extent of the myocardial ﬁbrosis that
occurs in NIDC (28). Measurement of T1 pre- and
post-contrast may further improve the discrimi-
nating ability of CMR-derived ﬁbrosis (24,25).
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953Other data exist for complementary MR and non-
MR biomarkers that may further aid risk stratiﬁ-
cation; these include serum biomarkers, ECG
parameters, and measurement of neurohormonal
activation, which were not measured in the study
(29–31).
CONCLUS IONS
Among patients with NIDC and a reduced EF
undergoing ICD implantation for the primary pre-
vention of SCD, the extent of myocardial scar by
LGE provides additive risk stratiﬁcation. This work
should promote further research efforts, and spe-
ciﬁcally a study in a large multicenter, prospectively
enrolled cohort to determine whether CMR incombination with other novel markers can help
identify high-risk patients who may beneﬁt from
more advanced care or low-risk patients for whom
conservative measures may be appropriate.Acknowledgments
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